» Articles » PMID: 38503931

Introducing Neurofilament Light Chain Measure in Psychiatry: Current Evidence, Opportunities, and Pitfalls

Overview
Journal Mol Psychiatry
Date 2024 Mar 20
PMID 38503931
Authors
Affiliations
Soon will be listed here.
Abstract

The recent introduction of new-generation immunoassay methods allows the reliable quantification of structural brain markers in peripheral matrices. Neurofilament light chain (NfL), a neuron-specific cytoskeletal component released in extracellular matrices after neuroaxonal impairment, is considered a promising blood marker of active brain pathology. Given its sensitivity to a wide range of neuropathological alterations, NfL has been suggested for the use in clinical practice as a highly sensitive, but unspecific tool to quantify active brain pathology. While large efforts have been put in characterizing its clinical profile in many neurological conditions, NfL has received far less attention as a potential biomarker in major psychiatric disorders. Therefore, we briefly introduce NfL as a marker of neuroaxonal injury, systematically review recent findings on cerebrospinal fluid and blood NfL levels in patients with primary psychiatric conditions and highlight the opportunities and pitfalls. Current evidence suggests an elevation of blood NfL levels in patients with major depression, bipolar disorder, psychotic disorders, anorexia nervosa, and substance use disorders compared to physiological states. However, blood NfL levels strongly vary across diagnostic entities, clinical stage, and patient subgroups, and are influenced by several demographic, clinical, and analytical factors, which require accurate characterization. Potential clinical applications of NfL measure in psychiatry are seen in diagnostic and prognostic algorithms, to exclude neurodegenerative disease, in the assessment of brain toxicity for different pharmacological compounds, and in the longitudinal monitoring of treatment response. The high inter-individual variability of NfL levels and the lack of neurobiological understanding of its release are some of the main current limitations. Overall, this primer aims to introduce researchers and clinicians to NfL measure in the psychiatric field and to provide a conceptual framework for future research directions.

Citing Articles

Serum NFL and neuropsychological performance over ∼8 years in women with and without HIV: a longitudinal repeated measures study.

Gustafson D, Li X, Baird A, Zetterberg H, Blennow K, Zhang J EClinicalMedicine. 2025; 80:103052.

PMID: 39911246 PMC: 11794164. DOI: 10.1016/j.eclinm.2024.103052.


Establishing Decisional Cutoff Values of Neurofilament Light Chains in Cerebrospinal Fluid Measured by Fully Automated Chemiluminescent Enzyme Immunoassay.

Agnello L, Gambino C, Del Ben F, Ciaccio A, Scazzone C, Ciaccio M J Clin Lab Anal. 2025; 39(4):e25152.

PMID: 39812240 PMC: 11848146. DOI: 10.1002/jcla.25152.


Neurofilament Light Protein as a Biomarker in Severe Mental Disorders: A Systematic Review.

Squitti R, Fiorenza A, Martinelli A, Brembati V, Crescenti D, Rongioletti M Int J Mol Sci. 2025; 26(1.

PMID: 39795920 PMC: 11719531. DOI: 10.3390/ijms26010061.


Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.

Kim S, Gomes A, Schindler P, Hyun J, Kim K, Lee D JAMA Neurol. 2024; 82(2):168-175.

PMID: 39714824 PMC: 11811799. DOI: 10.1001/jamaneurol.2024.4400.


Neurofilament light chain plasma levels in major depressive disorder: a brief research report.

Fernandez-Pereira C, Fernandez-Ceballos M, Olivares J, Prieto-Gonzalez J, Agis-Balboa R Front Psychiatry. 2024; 15:1476248.

PMID: 39611129 PMC: 11602450. DOI: 10.3389/fpsyt.2024.1476248.


References
1.
Preische O, Schultz S, Apel A, Kuhle J, Kaeser S, Barro C . Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. 2019; 25(2):277-283. PMC: 6367005. DOI: 10.1038/s41591-018-0304-3. View

2.
Logue M, van Rooij S, Dennis E, Davis S, Hayes J, Stevens J . Smaller Hippocampal Volume in Posttraumatic Stress Disorder: A Multisite ENIGMA-PGC Study: Subcortical Volumetry Results From Posttraumatic Stress Disorder Consortia. Biol Psychiatry. 2017; 83(3):244-253. PMC: 5951719. DOI: 10.1016/j.biopsych.2017.09.006. View

3.
Anderson A, Easley K, Kasher N, Franklin D, Heaton R, Zetterberg H . Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy. J Neurovirol. 2018; 24(6):695-701. PMC: 6279552. DOI: 10.1007/s13365-018-0664-y. View

4.
Ziemssen T, Akgun K, Czlonkowska A, Antos A, Bembenek J, Kurkowska-Jastrzebska I . Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations. Mov Disord. 2022; 37(5):1074-1079. DOI: 10.1002/mds.28946. View

5.
Insel T . Rethinking schizophrenia. Nature. 2010; 468(7321):187-93. DOI: 10.1038/nature09552. View